Last reviewed 2026-05-19 · How we verify

Bromazil (ENILCONAZOLE)

Phase 2 active Small molecule ✓ Verified May 2026

Bromazil (generic name: ENILCONAZOLE) is a enilconazole drug. It is currently in Phase 2 development.

Enilconazole works by inhibiting the enzyme indoleamine 2,3-dioxygenase 1, which is involved in the breakdown of tryptophan.

Bromazil is a small molecule with the synonyms AMOLDEN MP 100, BROMAZIL, CGA-41333, CLINAFARM, DECCOSIL, and DECCOZIL. Its exact mechanism and indications are not specified in the provided information.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	ENILCONAZOLE
Drug class	enilconazole
Target	Indoleamine 2,3-dioxygenase 1
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Think of tryptophan as a building block for the body's natural chemicals. Indoleamine 2,3-dioxygenase 1 is like a demolition crew that breaks down tryptophan. Enilconazole stops this demolition crew from working, allowing tryptophan to be used for other important functions.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Bromazil CI brief — competitive landscape report
Bromazil updates RSS · CI watch RSS

Frequently asked questions about Bromazil

What is Bromazil?

Bromazil (ENILCONAZOLE) is a enilconazole drug.

How does Bromazil work?

Enilconazole works by inhibiting the enzyme indoleamine 2,3-dioxygenase 1, which is involved in the breakdown of tryptophan.

What is the generic name of Bromazil?

ENILCONAZOLE is the generic (nonproprietary) name of Bromazil.

What drug class is Bromazil in?

Bromazil belongs to the enilconazole class. See all enilconazole drugs at /class/enilconazole.

What development phase is Bromazil in?

Bromazil is in Phase 2.

What does Bromazil target?

Bromazil targets Indoleamine 2,3-dioxygenase 1 and is a enilconazole.

Drug class: All enilconazole drugs
Target: All drugs targeting Indoleamine 2,3-dioxygenase 1
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing